Connect Sign In
ARUP CLARISPECT™ Multiple Myeloma MRD by Spectral Flow Cytometry
Spectral flow cytometry achieves greater diagnostic clarity to better facilitate care decisions, determining minimal residual disease (MRD) with greater confidence while requiring minimal specimen volume.
Analyzes
18
myeloma markers simultaneously
Consolidates
tubes, requiring less specimen volume
Achieves
2.8x10-6
sensitivity with 95% confidence
Reports
deep MRD status and immunophenotype
Returns results within
1-3 days
Characterize Cell Populations With Greater Confidence
Spectral flow cytometry captures emission data across the entire spectrum of light, enabling the simultaneous interrogation of more than 40 markers. By detecting all relevant markers on each cell, CLARISPECT characterizes cell populations with greater accuracy and confidence, particularly small neoplastic populations.
Attain Greater Insight With Less Sample Volume
Bone marrow is a precious, difficult-to-obtain specimen, and clinicians often need to extract as many data points as possible from each sample. CLARISPECT consolidates all relevant markers into a single tube, reducing the amount of sample volume required for analysis while also increasing sensitivity.
Sensitivity That Goes Beyond Clinical Standards
Spectral flow cytometry increases sensitivity beyond the capabilities of conventional flow cytometry. CLARISPECT Myeloma MRD can identify as few as 14 neoplastic cells in a population of 5 million analyzed cells with 95% confidence. CLARISPECT provides deep MRD profiling that will identify more patients who have residual disease.
Characterize Immunophenotype Without Original Clone
Spectral flow cytometry reports on the presence of aberrant cell populations and characterizes their immunophenotype without requiring the original clone or previous characterizations.
Assess MRD Efficiently
CLARISPECT assesses MRD with greater efficiency, faster, and at a significantly lower cost to the health system than other MRD assessment methods, such as NGS.
Why Choose ARUP
ARUP Laboratories is the first large reference laboratory in the United States to offer MRD assessment by spectral flow cytometry.
Proven Expertise Delivers Definitive Results
A select group of highly experienced hematopathologists, with subspecialty expertise, performs primary analysis and case interpretation. Their depth of expertise, built through high case volumes that include rare diseases, delivers highly accurate interpretations.
Results Returned Within 1–3 Days
Our laboratory signs out MRD cases daily and returns results within 1–3 days.
Rigorous Scrutiny Provides Exceptional Quality
Each MRD case undergoes multiple layers of review to ensure reliability of each interpretation.
